BDCA-2 (CD303): A highly specific marker for normal and neoplastic plasmacytoid dendritic cells

Blood

Volumn 122, Issue 2, 2013, Pages 296-297

  Boiocchi, Leonardo ^a   Lonardi, Silvia ^a   Vermi, William ^a   Fisogni, Simona ^a   Facchetti, Fabio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BDCA 2 ANTIBODY; BDCA 2 PROTEIN; CD123 ANTIGEN; CD2 ASSOCIATED PROTEIN; INTERFERON; LECTIN RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CLEC4C PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LECTIN; MEMBRANE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; DISEASE MARKER; HEMATOLOGIC DISEASE; HUMAN; LARGE CELL LYMPHOMA; LETTER; NEOPLASM; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ARTICLE; DENDRITIC CELL; METABOLISM; PATHOLOGY;

BIOLOGICAL MARKERS; DENDRITIC CELLS; HUMANS; LECTINS, C-TYPE; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC;

EID: 84884496875     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-500413     Document Type: Letter

References (10)

1. Montes-Moreno S, Ramos-Medina R, Martínez-López A, et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood. 2013;121(4):643-647.
2. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
3. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:76-79
4. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med. 2001;194(12):1823-1834. (Pubitemid 34028661)
5. Jaye DL, Geigerman CM, Herling M, Eastburn K, Waller EK, Jones D. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol. 2006;19(12):1555-1562. (Pubitemid 44789923)
6. Dargent JL, Delannoy A, Pieron P, Husson B, Debecker C, Petrella T. Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. J Cutan Pathol. 2011;38(11):893-898.
7. Vitte F, Fabiani B, Bénet C, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012;36(9):1302-1316.
8. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, Jaffe ES. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.
9. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.
10. Garnache-Ottou F, Feuillard J, Ferrand C, et al. GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636. Ricerca